PTC Therapeutics (PTCT) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) once again adopted a negative opinion on the annual renewal of the conditional marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD). In response to the news, the company's shares plunged 11.8% on Friday. Translarna is a protein restoration therapy designed to enable the formation of a functioning protein in patients with g ...